Mechanism for Tumor Progression in Lymphomatoid Papulosis: Hypothesis Based on Studies of Tumor Cell Lines Clonally Derived from Lymphomatoid Papulosis
Part of the
NATO ASI Series
book series (NSSA, volume 265)
Lymphomatoid papulosis (LyP) is a recurrent, multifocal cutaneous eruption characterized pathologically as an infiltration of large atypical cells surrounded by inflammatory cells (Macaulay, 1968). The large atypical cells resemble Reed Sternberg (RS) cells of Hodgkin disease (HD) (type A LyP cells), or Sézary cells of cutaneous T cell lymphoma (CTCL) (type B LyP cells) (Willemze et al., 1982). In most cases the large atypical cells have an activated helper T cell phenotype (CD30+, CD4+) (Kadin et al., 1985). Approximately 10–20% of LyP cases are associated with a malignant lymphoma, usually CTCL, HD, or a CD30+ large cell anaplastic lymphoma (ALCL), (Weinman and Ackerman, 1981; Willemze et al., 1982; Sanchez et al., 1983; Wantzin et al., 1985; Harrington et al., 1989; Kaudewitz et al., 1990). The skin lesions of LyP can precede, coexist with, or follow the associated lymphoma (Ibid).
KeywordsMycosis Fungoides Hodgkin Disease Affinity Label Lymphomatoid Papulosis Large Atypical Cell
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Cheifitz, S, B Like and J Massague, 1986. Cellular distribution of type I and type II receptors for transforming growth factor-ß. J. Biol. Chem.
, 261: 9972–9978.Google Scholar
Davis, TH, CC Morton, R. Miller-Cassman, SP Balk and ME Kadin, 1992. Hodgkin’s disease, lymphoblastoid papulosis, and cutaneous T cell lymphoma derived from a common T cell clone. N. Engl. J. Med.
, 326: 1115–1122.PubMedCrossRefGoogle Scholar
Ellingsworth, LR, JE Brennan, X Fok, DM Rosen, H Bentz, KA Piez and SM Seyedin, 1986. Antibodies to the N-terminal portion of cartilage-inducing factor A and transforming growth factor B. J. Biol. Chem.
, 261: 12362–12367.PubMedGoogle Scholar
Harrington, DS, SW Braddock, KS Blochr, DD Weisenburger, W Sanger and JO Armitage, 1989. Lymphomatoid papulosis and progression to T cell lymphoma: An immunophenotypic and genotypic analysis. J. Am. Acad. Dermatol.
, 21: 951–957.PubMedCrossRefGoogle Scholar
Jullien, P, TM Berg and DA Lawrence, 1989. Acidic cellular environments: Activation of latent TGF-beta and sensitization of cellular responses to TGF-ß and EGF. Int. J. Cancer
, 43: 886–891.PubMedCrossRefGoogle Scholar
Kadin, ME, 1985. Common activated helper T cell origin for lymphomatoid papulosis, mycosis fungoides and some types of Hodgkin’s disease. Lancet
ii: 864–865.CrossRefGoogle Scholar
Kadin, ME, K Nasu, D Sako, J Said and EC Vonderheid, 1985, Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin’s disease associated antigens. Am. J. Pathol.
, 119: 315–325.PubMedGoogle Scholar
Kadin, ME, MW Cavaille-Coll and CC Morton, 1990. Tumor progression in Ki-1+
cutaneous lymphomas is related to escape from inhibition by transforming growth factor-ß. Blood
, 76,Suppl 1, 354a.Google Scholar
Kadin, ME, J Butmarc, A Elovic and D Wong, 1993. Eosinophils are a major source of transforming growth factor-beta (TGF-β) in nodular sclerosing Hodgkin’s disease. Am. J.Pathol.
, 142: 11–16.PubMedGoogle Scholar
Kaudewitz, P, H Stein, G Plewig et al, 1990. Hodgkin’s disease followed by lymphomatoid papulosis: Immunophenotypical evidence for a close relationship between lymphomatoid papulosis and Hodgkin’s disease. J. Am. Acad. Dermatol.
, 22: 999–PubMedCrossRefGoogle Scholar
Kehrl, JH, AB Roberts, LM Wakefield, S Jakeloew, MB Sporn and AS Fauci, 1986. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med.
, 163: 1037–1050.PubMedCrossRefGoogle Scholar
Lyons, RM, LE Gentry, AF Purchio and HL Moses, 1990. Mechanism of activation of latent recombinant TGFβl by plasmin. J. Cell Biol.
, 110: 1361–1367.PubMedCrossRefGoogle Scholar
Massague, J and B Like, 1985. Cellular receptors for type B transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J. Biol. Chem.
, 260: 1626–1645.Google Scholar
McCaffrey, TA, DJ Falcone, CT Brayton, LA Agarwal, FGP Welt and BB Weksler, 1989. Transforming growth factor-ß activity is potentiated by heparin via dissociation of the transforming growth factor-α/ß-2-macroglobulin complex. J. Cell Biol.
, 109: 441–448.PubMedCrossRefGoogle Scholar
Macaulay, WL, 1968. Lymphomatoid papulosis: A continuing self healing eruption, clinically benign histologically malignant. Arch. Dermatol.
, 97: 23–30.PubMedCrossRefGoogle Scholar
Newcom, SR, ME Kadin and AA Ansari, 1988. Production of transforming growth factor-ß activity by Ki-l positive lymphoma cells and analysis of its role in the regulation of Ki-l positive lymphoma growth. Am. J. Pathol.
, 131: 569–577.PubMedGoogle Scholar
Sanchez, NP, MR Pittelkow, SA Muller, PM Banks and RK Winkelmann, 1983. The clinicopathologic spectrum of lymphomatoid papulosis: Study of 31 cases. J. Am. Acad. Dermatol.
, 8: 81–94.PubMedCrossRefGoogle Scholar
Wantzin, GL, K Thomsen, F Brandup and JK Larsen, 1985. Lymphomatoid papulosis. Development into cutaneous T cell lymphoma. Arch. Dermatol.
, 121: 792–794.PubMedCrossRefGoogle Scholar
Weinman, VF and AB Ackerman, 1981. Lymphomatoid papulosis. A critical review and new findings. Am. J. Dermatopathol.
, 3: 129–163.PubMedCrossRefGoogle Scholar
Willemze, R, CJ Meyer, WA van Vloten and E Scheffer, 1982. The clinical and histological spectrum of lymphomatoid papulosis. Br. J. Dermatol.
, 107: 131–144.PubMedCrossRefGoogle Scholar
© Springer Science+Business Media New York 1994